Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research report on Friday, January 10th.

Aptose Biosciences Stock Performance

APTO stock opened at $0.18 on Friday. The company has a market capitalization of $10.60 million, a PE ratio of -0.06 and a beta of 0.88. The company’s fifty day moving average price is $0.21 and its 200-day moving average price is $0.35. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.20.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned 1.17% of Aptose Biosciences worth $158,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.